PT  - JOURNAL ARTICLE
AU  - Mufti, Kheireddin
AU  - Rudakou, Uladzislau
AU  - Yu, Eric
AU  - Ruskey, Jennifer A.
AU  - Asayesh, Farnaz
AU  - Laurent, Sandra B.
AU  - Spiegelman, Dan
AU  - Arnulf, Isabelle
AU  - Hu, Michele T.M.
AU  - Montplaisir, Jacques Y.
AU  - Gagnon, Jean-François
AU  - Desautels, Alex
AU  - Dauvilliers, Yves
AU  - Gigli, Gian Luigi
AU  - Valente, Mariarosaria
AU  - Janes, Francesco
AU  - Högl, Birgit
AU  - Stefani, Ambra
AU  - Holzknecht, Evi
AU  - Sonka, Karel
AU  - Kemlink, David
AU  - Oertel, Wolfgang
AU  - Janzen, Annette
AU  - Plazzi, Giuseppe
AU  - Antelmi, Elena
AU  - Figorilli, Michela
AU  - Puligheddu, Monica
AU  - Mollenhauer, Brit
AU  - Trenkwalder, Claudia
AU  - Sixel-Döring, Friederike
AU  - De Cock, Valérie Cochen
AU  - Monaca, Christelle Charley
AU  - Heidbreder, Anna
AU  - Ferini-Strambi, Luigi
AU  - Dijkstra, Femke
AU  - Viaene, Mineke
AU  - Abril, Beatriz
AU  - Boeve, Bradley F.
AU  - Postuma, Ronald B.
AU  - Rouleau, Guy A.
AU  - Gan-Or, Ziv
TI  - A comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder
AID  - 10.1101/2020.03.17.20032664
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.17.20032664
4099  - http://medrxiv.org/content/early/2020/03/20/2020.03.17.20032664.short
4100  - http://medrxiv.org/content/early/2020/03/20/2020.03.17.20032664.full
AB  - Objective To examine the role of autosomal dominant (AD) and recessive (AR) Parkinsonism genes in the risk of isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD).Methods Ten genes implicated in AD and AR Parkinsonism were fully sequenced using targeted next-generation sequencing in 1,039 iRBD patients and 1,852 controls of European ancestry. These include the AR genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7 and PLA2G6, and the AD genes LRRK2, GCH1 and VPS35. To examine the role of rare heterozygous variants in these genes, burden test and SKAT-O analyses were performed. The contribution of homozygous and compound heterozygous variants was further examined in the AR genes. Copy number variants (CNVs) in PRKN were tested in a subset of samples (n=374) using multiplex ligation-dependent probe amplification followed by analysis of all samples using ExomeDepth.Results We found no association between rare heterozygous variants in the tested genes and risk for iRBD. Several homozygous and compound heterozygous carriers were identified with variants of unknown significance, yet there was no overrepresentation in iRBD patients versus controls.Conclusion Our results do not support a major role for variants in PRKN, PARK7, PINK1, VPS13C, ATP13A2, FBXO7, PLA2G6, LRRK2, GCH1 and VPS35 in the risk of iRBD.Competing Interest StatementKheireddin Mufti – Reports no conflict of interest to disclose. Uladislau Rudakou - Reports no conflict of interests to disclose. Eric Yu - Reports no conflict of interests to disclose. Jennifer A. Ruskey – Reports no conflict of interests to disclose. Farnaz Asayesh – Reports no conflict of interests to disclose. Sandra B. Laurent – Reports no conflict of interests to disclose. Dan Spiegelman – Reports no conflict of interests to disclose. Isabelle Arnulf – Received fees for speaking engagements from UCB pharma, consultancy for Roche, Novartis, and Ono Pharma. Michele T.M. Hu – Received consultancy fees from Roche and Biogen Pharmaceuticals. Jacques Y. Montplaisir – Received consultancy fees from Eisai Co. Jean-François Gagnon – Reports research funding from the Canadian Institutes of Health Research (CIHR). Alex Desautels – Received grants from Flamel Ireland, Pfized, Biron, Canopy Growth, as well as fees for speaking engagements from Biogen and from consultancy from UCB pharma. Yves Dauvilliers – Reports no conflict of interests to disclose. Gian Luigi Gigli – Reports no conflict of interests to disclose. Mariarosaria Valente – Reports no conflict of interests to disclose. Francesco Janes - Reports no conflict of interests to disclose. Birgit Högl – Received consultancy fees from Axovant, benevolent Bio, Takeda, Roche, ono, and received speaker honoraria from Eli Lilly, Mundipharma, UCB, Abbvie, Inspire, Lundbeck. Ambra Stefani – Reports no conflict of interests to disclose. Evi Holzknecht – Reports no conflict of interests to disclose. Karel Sonka – Reports no conflict of interests to disclose. David Kemlink – Reports no conflict of interests to disclose. Wolfgang Oertel – Reports no conflict of interests related to the study. He received consultancy or speaker fees from Adamas, Abbvie, Desitin, Novartis and Roche. He has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and Roche Pharma, Basel, Switzerland. Annette Janzen – Reports no conflict of interests to disclose. She has received research funding from Parkinson Fonds Deutschland. Giuseppe Plazzi – Reports no conflict of interests to disclose. Elena Antelmi – Reports no conflict of interests to disclose. Michela Figorilli – Reports no conflict of interests to disclose. Monica Puligheddu – Reports no conflict of interests to disclose. Brit Mollenhauer – Has received honoraria for consultancy from Roche, Biogen, UCB and Sun Pharma Advanced Research Company. BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson’s Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for Parkinson’s Research. Claudia Trenkwalder – Honoraria for lectures from UCB, Grünenthal, Otsuka and consultancy fees from Britannia Pharmaceuticals and Roche. Friederike Sixel-Döring – Honoraria for lectures from Abbott, Desitin, Grünenthal, Licher MT, STADA Pharm, UCB. Seminar fees from Boston Scientific, Licher MT. Serves on an advisory board for STADA Pharm. No conflict of interest with the presented study. Valérie Cochen De Cock – Reports no conflict of interests to disclose. Christelle Charley Monaca – Reports no conflict of interests to disclose. Anna Heidbreder – Reports no conflict of interests to disclose. Luigi Ferini-Strambi – Reports no conflict of interests to disclose. Femke Dijkstra – Reports no conflict of interests to disclose. Mineke Viaene – Reports no conflict of interests to disclose. Beatriz Abril – Reports no conflict of interests to disclose. Bradley F. Boeve – Dr. Boeve has served as an investigator for clinical trials sponsored by Biogen and Alector. He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the LBD Functional Genomics Program. Ronald B. Postuma – Reports grants and Fonds de la Recherche en Sante, as well as grants from the the Canadian Institute of Health Research, The Parkinson Society of Canada, the WestonGarfield Foundation, the Michael J. Fox Foundation, and the Webster Foundation, as well as personal fees from Takeda, Roche, Teva Neurosciences, Novartis Canada, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, Jazz Pharmaceuticals, Abbvie, Jannsen, Otsuko, Phytopharmics, and Inception Sciences. Guy A. Rouleau – Reports no conflict of interests to disclose. Ziv Gan-Or – Received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali and Deerfield. Funding StatementThis work was financially supported by the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), Parkinson Canada the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program. The Montreal cohort was funded by the Canadian Institutes of Health Research (CIHR) and the W. Garfield Weston Foundation. The Oxford Discovery study is funded by the Monument Trust Discovery Award from Parkinson’s UK and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford, the NIHR Clinical Research Network and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for the analysis is available in the supplementary tables. Anonymized raw data can be shared upon request from any qualified investigator.ATP13A2Probable cation-transporting ATPase 13A2ADAutosomal dominantARAutosomal recessiveCNVsCopy number variantsFBXO7F-box only protein 7GCH1GTP cyclohydrolase IiRBDIsolated rapid eye movement (REM) sleep behavior disorderLRRK2Leucine-rich repeat kinase 2MIPsMolecular Inversion ProbesNGSNext generation sequencingPARK7Parkinson disease protein 7PDParkinson’s diseasePINK1PTEN-induced kinase 1PLA2G685 kDa calcium-independent phospholipase A2PRKNParkinson disease protein 2VPS13CVacuolar protein sorting-associated protein 13CVPS35Vacuolar protein sorting-associated protein 35.